Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 61
Filtrar
1.
Dig Dis Sci ; 69(6): 2109-2122, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38564148

RESUMO

BACKGROUND: Cholesterol ester storage disorder (CESD; OMIM: 278,000) was formerly assumed to be an autosomal recessive allelic genetic condition connected to diminished lysosomal acid lipase (LAL) activity due to LIPA gene abnormalities. CESD is characterized by abnormal liver function and lipid metabolism, and in severe cases, liver failure can occur leading to death. In this study, one Chinese nonclassical CESD pedigree with dominant inheritance was phenotyped and analyzed for the corresponding gene alterations. METHODS: Seven males and eight females from nonclassical CESD pedigree were recruited. Clinical features and LAL activities were documented. Whole genome Next-generation sequencing (NGS) was used to screen candidate genes and mutations, Sanger sequencing confirmed predicted mutations, and qPCR detected LIPA mRNA expression. RESULTS: Eight individuals of the pedigree were speculatively thought to have CESD. LAL activity was discovered to be lowered in four living members of the pedigree, but undetectable in the other four deceased members who died of probable hepatic failure. Three of the four living relatives had abnormal lipid metabolism and all four had liver dysfunctions. By liver biopsy, the proband exhibited diffuse vesicular fatty changes in noticeably enlarged hepatocytes and Kupffer cell hyperplasia. Surprisingly, only a newly discovered heterozygous mutation, c.1133T>C (p. Ile378Thr) on LIPA, was found by gene sequencing in the proband. All living family members who carried the p.I378T variant displayed reduced LAL activity. CONCLUSIONS: Phenotypic analyses indicate that this may be an autosomal dominant nonclassical CESD pedigree with a LIPA gene mutation.


Assuntos
Doença do Armazenamento de Colesterol Éster , Heterozigoto , Linhagem , Esterol Esterase , Humanos , Masculino , Feminino , Doença do Armazenamento de Colesterol Éster/genética , Doença do Armazenamento de Colesterol Éster/diagnóstico , Esterol Esterase/genética , Adulto , Mutação , Genes Dominantes , Pessoa de Meia-Idade , Fenótipo , Adolescente , Criança
3.
J. pediatr. (Rio J.) ; J. pediatr. (Rio J.);98(1): 4-14, Jan.-Feb. 2022. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1360556

RESUMO

Abstract Objective: Lysosomal acid lipase deficiency (LAL-D) is an underdiagnosed autosomal recessive disease with onset between the first years of life and adulthood. Early diagnosis is crucial for effective therapy and long-term survival. The objective of this article is to recognize warning signs among the clinical and laboratory characteristics of LAL-D in pediatric patients through a scope review. Sources: Electronic searches in the Embase, PubMed, Livivo, LILACS, Web of Science, Scopus, Google Scholar, Open Gray, and ProQuest Dissertations and Theses databases. The dataset included observational studies with clinical and laboratory characteristics of infants, children and adolescents diagnosed with lysosomal acid lipase deficiency by enzyme activity testing or analysis of mutations in the lysosomal acid lipase gene (LIPA). The reference selection process was performed in two stages. The references were selected by two authors, and the data were extracted in June 2020. Summary of the findings: The initial search returned 1593 studies, and the final selection included 108 studies from 30 countries encompassing 206 patients, including individuals with Wolman disease and cholesteryl ester storage disease (CESD). The most prevalent manifestations in both spectra of the disease were hepatomegaly, splenomegaly, anemia, dyslipidemia, and elevated transaminases. Conclusions: Vomiting, diarrhea, jaundice, and splenomegaly may be correlated, and may serve as a starting point for investigating LAL-D. Familial lymphohistiocytosis should be part of the differential diagnosis with LAL-D, and all patients undergoing upper gastrointestinal endoscopy should be submitted to intestinal biopsy.


Assuntos
Humanos , Lactente , Criança , Adolescente , Adulto , Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/genética , Doença do Armazenamento de Colesterol Éster/tratamento farmacológico , Doença de Wolman/diagnóstico , Doença de Wolman/genética , Esterol Esterase/genética , Esterol Esterase/uso terapêutico , Hepatomegalia
4.
J Pediatr (Rio J) ; 98(1): 4-14, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-33964214

RESUMO

OBJECTIVE: Lysosomal acid lipase deficiency (LAL-D) is an underdiagnosed autosomal recessive disease with onset between the first years of life and adulthood. Early diagnosis is crucial for effective therapy and long-term survival. The objective of this article is to recognize warning signs among the clinical and laboratory characteristics of LAL-D in pediatric patients through a scope review. SOURCES: Electronic searches in the Embase, PubMed, Livivo, LILACS, Web of Science, Scopus, Google Scholar, Open Gray, and ProQuest Dissertations and Theses databases. The dataset included observational studies with clinical and laboratory characteristics of infants, children and adolescents diagnosed with lysosomal acid lipase deficiency by enzyme activity testing or analysis of mutations in the lysosomal acid lipase gene (LIPA). The reference selection process was performed in two stages. The references were selected by two authors, and the data were extracted in June 2020. SUMMARY OF THE FINDINGS: The initial search returned 1593 studies, and the final selection included 108 studies from 30 countries encompassing 206 patients, including individuals with Wolman disease and cholesteryl ester storage disease (CESD). The most prevalent manifestations in both spectra of the disease were hepatomegaly, splenomegaly, anemia, dyslipidemia, and elevated transaminases. CONCLUSIONS: Vomiting, diarrhea, jaundice, and splenomegaly may be correlated, and may serve as a starting point for investigating LAL-D. Familial lymphohistiocytosis should be part of the differential diagnosis with LAL-D, and all patients undergoing upper gastrointestinal endoscopy should be submitted to intestinal biopsy.


Assuntos
Doença do Armazenamento de Colesterol Éster , Doença de Wolman , Adolescente , Adulto , Criança , Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/tratamento farmacológico , Doença do Armazenamento de Colesterol Éster/genética , Hepatomegalia , Humanos , Lactente , Esterol Esterase/genética , Esterol Esterase/uso terapêutico , Doença de Wolman/diagnóstico , Doença de Wolman/genética , Doença de Wolman
5.
Clin Chim Acta ; 519: 64-69, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-33857477

RESUMO

BACKGROUND: Lysosomal acid lipase deficiency (LALD, OMIM#278000) is a rare lysosomal disorder with an autosomal recessive inheritance. The main clinical manifestations are related to a progressive accumulation of cholesteryl esters, triglycerides or both within the lysosome in different organs such as the liver, spleen, and cardiovascular system. A wide range of clinical severity is associated with LALD including a severe very rare antenatal/neonatal/infantile phenotype named Wolman disease and a late-onset form named cholesteryl ester storage disease (CESD). METHODS: This study aimed to investigate a cohort of at-risk patients (4174) presenting with clinical or biological signs consistent with LALD using the assessment of LAL activity on dried blood spots. RESULTS: LAL activity was lower than 0.05 nmol/punch/L (cut-off: 0.12) in 19 patients including 13 CESD and 6 Wolman. Molecular study has been conducted in 17 patients and succeeded in identifying 34 mutated alleles. Fourteen unique variants have been characterized, 7 of which are novel. CONCLUSION: This study allowed to identify a series of patients and expanded the molecular spectrum knowledge of LALD. Besides, a new screening criteria grid based on the clinical/biological data from our study and the literature has been proposed in order to enhance the diagnosis rate in at risk populations.


Assuntos
Doença do Armazenamento de Colesterol Éster , Doença de Wolman , Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/genética , Ésteres do Colesterol , Feminino , Humanos , Recém-Nascido , Lipase , Gravidez , Esterol Esterase/genética , Doença de Wolman/diagnóstico , Doença de Wolman/genética
6.
Turk J Pediatr ; 62(5): 831-835, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33108087

RESUMO

BACKGROUND: Lysosomal acid lipase deficiency (LAL-D), also known as cholesteryl ester storage disease or Wolman disease, is a multi-systemic autosomal recessive genetic disorder caused by mutations in the lysosomal acid lipase gene (LIPA). CASE: A 14-year-old female patient was diagnosed as LAL-D with the findings of hepatomegaly, splenomegaly, elevated liver enzyme levels, and abnormal lipid profile. Her sister had similar laboratory and ultrasonographic findings. Both siblings had a homozygous c.894 G > A mutation in the LIPA gene, and their parents were heterozygous for this mutation. CONCLUSIONS: This case is one of the similar reports in the literature regarding clinical, biochemical, and genetic findings. It is well-known that LAL-D has overlapping clinical manifestations, and early diagnosis is quite challenging. Therefore, most patients die in the first year of life. After the determination of novel mutations in LAL-D patients, it is thought that LAL-D can present with heterogeneous signs and symptoms.


Assuntos
Doença do Armazenamento de Colesterol Éster , Dislipidemias , Doença de Wolman , Adolescente , Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/genética , Feminino , Hepatomegalia/genética , Humanos , Doença de Wolman/diagnóstico , Doença de Wolman/genética , Doença de Wolman
7.
J Pediatr Gastroenterol Nutr ; 71(6): 726-730, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32740531

RESUMO

Lysosomal acid lipase (LAL) deficiency, or cholesterol ester storage disease, is a disorder affecting the breakdown of cholesterol esters and triglycerides within lysosomes. Clinical findings include hepatomegaly, hepatic dysfunction, and dyslipidemia with a wide range of phenotypic variability and age of onset. The available clinical and molecular information of the patient presented herein was consistent with a diagnosis of LAL deficiency, but her LAL activity assay repeatedly showed normal or borderline low results. Her response to enzyme replacement therapy and demonstrable deficiency on a newer specific enzymatic assay ultimately confirmed her diagnosis of LAL deficiency.


Assuntos
Doença do Armazenamento de Colesterol Éster , Esterol Esterase , Doença de Wolman , Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/tratamento farmacológico , Doença do Armazenamento de Colesterol Éster/genética , Feminino , Humanos , Esterol Esterase/genética , Esterol Esterase/uso terapêutico , Doença de Wolman/diagnóstico , Doença de Wolman/tratamento farmacológico , Doença de Wolman/genética , Doença de Wolman
8.
J Lipid Res ; 61(8): 1192-1202, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32482718

RESUMO

Lysosomal acid lipase (LAL) is a serine hydrolase that hydrolyzes cholesteryl ester (CE) and TGs delivered to the lysosomes into free cholesterol and fatty acids. LAL deficiency due to mutations in the LAL gene (LIPA) results in accumulation of TGs and cholesterol esters in various tissues of the body leading to pathological conditions such as Wolman's disease and CE storage disease (CESD). Here, we present the first crystal structure of recombinant human LAL (HLAL) to 2.6 Å resolution in its closed form. The crystal structure was enabled by mutating three of the six potential glycosylation sites. The overall structure of HLAL closely resembles that of the evolutionarily related human gastric lipase (HGL). It consists of a core domain belonging to the classical α/ß hydrolase-fold family with a classical catalytic triad (Ser-153, His-353, Asp-324), an oxyanion hole, and a "cap" domain, which regulates substrate entry to the catalytic site. Most significant structural differences between HLAL and HGL exist at the lid region. Deletion of the short helix, 238NLCFLLC244, at the lid region implied a possible role in regulating the highly hydrophobic substrate binding site from self-oligomerization during interfacial activation. We also performed molecular dynamic simulations of dog gastric lipase (lid-open form) and HLAL to gain insights and speculated a possible role of the human mutant, H274Y, leading to CESD.


Assuntos
Doença do Armazenamento de Colesterol Éster/enzimologia , Esterol Esterase/química , Esterol Esterase/metabolismo , Doença do Armazenamento de Colesterol Éster/genética , Cristalografia por Raios X , Glicosilação , Humanos , Modelos Moleculares , Mutação , Domínios Proteicos , Esterol Esterase/genética
9.
Atherosclerosis ; 297: 8-15, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-32058863

RESUMO

BACKGROUND AND AIMS: Cholesteryl ester storage disease (CESD) due to LIPA gene mutations is characterized by hepatic steatosis, hypercholesterolemia and hypoalphalipoproteinemia, exposing affected patients to an increased cardiovascular risk. Further insights into the impact of LIPA gene mutations on lipid/lipoprotein metabolism are limited. Aim of the study was to investigate the effect of carrying one or two mutant LIPA alleles on lipoprotein composition and function. METHODS: Lipoproteins were isolated from 6 adult CESD patients, 5 relatives carrying one mutant LIPA allele (carriers) and 12 sex/age matched controls. Lipid profile, lipoprotein mass composition and the fatty acid distribution of cholesteryl esters (CEs) were assessed. HDL function was evaluated as the ability to promote nitric oxide release by endothelial cells. RESULTS: Despite the lipid-lowering therapy, total cholesterol, LDL-cholesterol and triglycerides were increased in CESD patients compared to controls, while HDL-cholesterol was reduced. Carriers also displayed elevated total and LDL-cholesterol. Very low and intermediate density lipoproteins from CESD patients and carriers were enriched in CEs compared to the control ones, with a concomitant reduction of triglycerides. Fatty acid composition of CEs in serum and lipoproteins showed a depletion of linoleate content in CESD patients, due to the reduced LCAT activity. In CESD HDL, fatty acid distribution of CEs was shifted towards saturated ones, if compared to control HDL. The changes in HDL composition did not affect HDL ability to promote nitric oxide release by endothelial cells. CONCLUSIONS: LIPA gene mutations significantly affected plasma levels and lipid composition of lipoproteins, likely contributing to the increased cardiovascular risk of affected patients.


Assuntos
Acetil-CoA C-Acetiltransferase/metabolismo , Doença do Armazenamento de Colesterol Éster/sangue , Doença do Armazenamento de Colesterol Éster/genética , Ésteres do Colesterol/sangue , Lipoproteínas/sangue , Mutação , Esterol Esterase/genética , Adolescente , Adulto , Idoso , Biomarcadores/sangue , Estudos de Casos e Controles , Células Cultivadas , Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/enzimologia , HDL-Colesterol , LDL-Colesterol/sangue , Feminino , Predisposição Genética para Doença , Células Endoteliais da Veia Umbilical Humana/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Óxido Nítrico/metabolismo , Fenótipo , Fosfatidilcolina-Esterol O-Aciltransferase/metabolismo , Triglicerídeos/sangue , Adulto Jovem
10.
Ann Hepatol ; 18(4): 646-650, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31182375

RESUMO

INTRODUCTION AND OBJECTIVES: Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive disease caused by mutations in the LIPA gene, located on the long arm of chromosome 10 (10q23.31). Up until now, more than 59 mutations have been described and which are the cause of a very wide clinical spectrum. The goal of this study was to identify the mutations present in Mexican pediatric patients with a diagnosis of LAL-D. MATERIALS AND METHODS: A cross-sectional study was carried out which included all the pediatric patients with LAL-D treated in a tertiary hospital in Mexico from January 2000 to June 2017. RESULTS: Sixteen patients with LAL-D were identified with a disease phenotype marked by the accumulation of cholesteryl esters. Eight distinct variants in the LIPA gene sequence were found, four pathogenic variants and four probably pathogenic. In six individuals, the variants were found in the homozygous state and ten were compound heterozygous. The eight variants were inverted, with five found on exon 4 and the others on exons 2, 8 and 10. The variant c.386A>G;p.His129Arg was the most common, being found in six of the 16 individuals (37.5%), making it much more frequent than what had previously been reported in the literature in proportion to the rest of the variants. The mutation known as E8SJM, which has been the mostly frequently found at the international level, was not the most common among this group of Mexican patients. In conclusion, Mexican patients present a different frequency of mutations associated with LAL-D in comparison to European populations.


Assuntos
Doença do Armazenamento de Colesterol Éster/genética , Esterol Esterase/genética , Doença de Wolman/genética , Criança , Estudos Transversais , Feminino , Humanos , Masculino , México , Mutação , Doença de Wolman
11.
Ann Clin Biochem ; 56(1): 112-117, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30056760

RESUMO

BACKGROUND AND AIM: Familial hypercholesterolaemia is caused by variants in the low-density lipoprotein cholesterol metabolic pathway involving LDLR, APOB and PCSK9 genes. A national genetic testing service in Wales, UK has observed that no familial hypercholesterolaemia variant is found in almost 80% patients with the familial hypercholesterolaemia phenotype. It has recently been suggested that some adult patients with a familial hypercholesterolaemia phenotype may have cholesteryl ester storage disease which can also present as a mixed hyperlipidaemia. The commonest genetic cause of cholesteryl ester storage disease is an exon 8 splice junction variant in the LIPA gene (rs116928232, c.894G>A; E8SJM) previously found to have an allele frequency of 0.0011 (1 in 450 individuals) in a large European population. This study investigated the prevalence of the E8SJM in patients with a familial hypercholesterolaemia phenotype in Wales, UK. METHOD: A total of 1203 patients with a clinical suspicion of familial hypercholesterolaemia but no familial hypercholesterolaemia variant were invited to participate. Of these, 668 patients provided informed written consent. Stored DNA samples from 663 patients were genotyped for the E8SJM variant. RESULTS: Three heterozygotes were identified (allele frequency 0.0023). Whole gene sequencing of the LIPA gene was undertaken in these three individuals, but no other variants were found. Therefore, there were no cholesteryl ester storage disease patients (homozygote or compound heterozygote) identified in this cohort. CONCLUSION: The allele frequency 0.0023 (1 in 221 individuals) for the E8SJM variant was more prevalent in this cohort than in a European population study; however, no cholesteryl ester storage disease homozygotes were identified. We found no evidence to support routine testing for cholesteryl ester storage disease in adult patients with a familial hypercholesterolaemia phenotype.


Assuntos
Doença do Armazenamento de Colesterol Éster/epidemiologia , Hiperlipoproteinemia Tipo II/epidemiologia , Adulto , Idoso , Doença do Armazenamento de Colesterol Éster/genética , Estudos de Coortes , Heterozigoto , Homozigoto , Humanos , Hiperlipoproteinemia Tipo II/genética , Hiperlipoproteinemia Tipo V/epidemiologia , Hiperlipoproteinemia Tipo V/genética , Masculino , Pessoa de Meia-Idade , Prevalência , Esterol Esterase/genética , País de Gales , Adulto Jovem
12.
J Pediatr Gastroenterol Nutr ; 67(4): 452-457, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-29958253

RESUMO

BACKGROUND: Lysosomal acid lipase deficiency (LAL-D) is a rare autosomal recessive lysosomal lipid storage disorder that results in an early-onset, severe, and lethal phenotype, known as Wolman disease, or a late-onset, attenuated phenotype, cholesteryl ester storage disease (CESD). The aim of our study was to describe the clinical presentation of CESD, focusing on the first noted abnormalities in patients. A diagnostic algorithm of CESD was also proposed. METHODS: This is an observational, 1-center study of 19 Polish patients with late-onset LAL-D. RESULTS: The mean age at which the first symptoms were reported was 4 years and 6 months. A mild hepatomegaly was the most common initial abnormality observed in all (100%) patients. Seven (37%) patients were noted to have mildly to moderately elevated serum transaminases. At the time of first hospitalization all (100%) patients presented with hepatomegaly, 15 (79%) patients presented with elevated serum transaminases and all (100%) patients had dyslipidemia. The mean age at the time of CESD diagnosis was 7 years and 2 months. Diagnoses were based on a deficient LAL activity in leukocytes (in all patients) and the LIPA gene mutations (in 47% of them). All the patients were carriers for the mutation c.894G>A in the LIPA gene. There was approximately a 3-year delay from initial symptoms to final diagnosis. CONCLUSIONS: Hepatomegaly constitutes the most common presenting clinical sign of CESD. Hepatomegaly and dyslipidemia defined as elevated serum total and LDL cholesterol, elevated triglycerides and normal to low HDL cholesterol, comprises the most characteristic findings at CESD diagnosis.


Assuntos
Algoritmos , Doença do Armazenamento de Colesterol Éster/diagnóstico , Dislipidemias/diagnóstico , Hepatomegalia/diagnóstico , Esterol Esterase/análise , Criança , Pré-Escolar , Doença do Armazenamento de Colesterol Éster/genética , Dislipidemias/sangue , Dislipidemias/genética , Feminino , Hepatomegalia/sangue , Hepatomegalia/genética , Humanos , Masculino , Mutação , Polônia , Esterol Esterase/genética , Transaminases/sangue
13.
Mol Genet Metab ; 123(2): 169-176, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29196158

RESUMO

Lysosomal acid lipase hydrolyzes cholesteryl esters and triglycerides contained in low density lipoprotein. Patients who are homozygous or compound heterozygous for mutations in the lysosomal acid lipase gene (LIPA), and have some residual enzymatic activity, have cholesteryl ester storage disease. One of the clinical features of this disease is hypercholesterolemia. Thus, patients with hypercholesterolemia who do not carry a mutation as a cause of autosomal dominant hypercholesterolemia, may actually have cholesteryl ester storage disease. In this study we have performed DNA sequencing of LIPA in 3027 hypercholesterolemic patients who did not carry a mutation as a cause of autosomal dominant hypercholesterolemia. Functional analyses of possibly pathogenic mutations and of all mutations in LIPA listed in The Human Genome Mutation Database were performed to determine the pathogenicity of these mutations. For these studies, HeLa T-REx cells were transiently transfected with mutant LIPA plasmids and Western blot analysis of cell lysates was performed to determine if the mutants were synthesized in a normal fashion. The enzymatic activity of the mutants was determined in lysates of the transfected cells using 4-methylumbelliferone-palmitate as the substrate. A total of 41 mutations in LIPA were studied, of which 32 mutations were considered pathogenic by having an enzymatic activity <10% of normal. However, none of the 3027 hypercholesterolemic patients were homozygous or compound heterozygous for a pathogenic mutation. Thus, cholesteryl ester storage disease must be a very rare cause of hypercholesterolemia in Norway.


Assuntos
Doença do Armazenamento de Colesterol Éster/epidemiologia , Doença do Armazenamento de Colesterol Éster/genética , Hipercolesterolemia/fisiopatologia , Mutação , Esterol Esterase/genética , Adulto , Doença do Armazenamento de Colesterol Éster/enzimologia , Feminino , Células HeLa , Homozigoto , Humanos , Masculino , Pessoa de Meia-Idade , Noruega/epidemiologia , Fenótipo , Prevalência
14.
Neth J Med ; 73(3): 129-32, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25852113

RESUMO

Cholesteryl ester storage disease (CESD) is a rare autosomal recessive disease caused by mutations in LIPA. Here we describe two different clinical presentations of this disease: one case with a clear phenotype of familial hypercholesterolaemia and one case with hepatosplenomegaly from childhood onwards. These two cases exemplify the diversity of clinical phenotypes of patients with CESD. Knowledge on the phenotypic variability of the disease is of clinical relevance in light of enzyme replacement therapy (sebelipase alpha) for patients with mutations in LIPA, which is currently under development.


Assuntos
Doença do Armazenamento de Colesterol Éster/genética , DNA/genética , Hepatomegalia/genética , Hipercolesterolemia/genética , Mutação , Esplenomegalia/genética , Esterol Esterase/genética , Adulto , Doença do Armazenamento de Colesterol Éster/metabolismo , Análise Mutacional de DNA , Feminino , Hepatomegalia/metabolismo , Humanos , Hipercolesterolemia/metabolismo , Masculino , Fenótipo , Esplenomegalia/metabolismo , Esterol Esterase/metabolismo , Adulto Jovem
15.
Biochem Biophys Res Commun ; 454(1): 162-6, 2014 Nov 07.
Artigo em Inglês | MEDLINE | ID: mdl-25450374

RESUMO

Sterol O-acyltransferase 2 (SOAT2), also known as ACAT2, is the major cholesterol esterifying enzyme in the liver and small intestine (SI). Esterified cholesterol (EC) carried in certain classes of plasma lipoproteins is hydrolyzed by lysosomal acid lipase (LAL) when they are cleared from the circulation. Loss-of-function mutations in LIPA, the gene that encodes LAL, result in Wolman disease (WD) or cholesteryl ester storage disease (CESD). Hepatomegaly and a massive increase in tissue EC levels are hallmark features of both disorders. While these conditions can be corrected with enzyme replacement therapy, the question arose as to what effect the loss of SOAT2 function might have on tissue EC sequestration in LAL-deficient mice. When weaned at 21 days, Lal(-)(/)(-):Soat2(+)(/)(+) mice had a whole liver cholesterol content (mg/organ) of 24.7 mg vs 1.9mg in Lal(+/+):Soat2(+/+) littermates, with almost all the excess sterol being esterified. Over the next 31 days, liver cholesterol content in the Lal(-)(/)(-):Soat2(+)(/)(+) mice increased to 145 ± 2 mg but to only 29 ± 2 mg in their Lal(-)(/)(-):Soat2(-)(/)(-) littermates. The level of EC accumulation in the SI of the Lal(-)(/)(-):Soat2(-)(/)(-) mice was also much less than in their Lal(-)(/)(-):Soat2(+)(/)(+) littermates. In addition, there was a >70% reduction in plasma transaminase activities in the Lal(-)(/)(-):Soat2(-)(/)(-) mice. These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.


Assuntos
Ésteres do Colesterol/metabolismo , Esterol Esterase/deficiência , Esterol O-Aciltransferase/deficiência , Alanina Transaminase/sangue , Animais , Aspartato Aminotransferases/sangue , Doença do Armazenamento de Colesterol Éster/genética , Doença do Armazenamento de Colesterol Éster/metabolismo , Modelos Animais de Doenças , Progressão da Doença , Feminino , Humanos , Intestino Delgado/metabolismo , Fígado/metabolismo , Masculino , Camundongos , Camundongos Knockout , Esterol Esterase/genética , Esterol O-Aciltransferase/genética , Esterol O-Aciltransferase 2
16.
Am J Physiol Gastrointest Liver Physiol ; 307(8): G836-47, 2014 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-25147230

RESUMO

Cholesteryl ester storage disease (CESD) results from loss-of-function mutations in LIPA, the gene that encodes lysosomal acid lipase (LAL). Hepatomegaly and deposition of esterified cholesterol (EC) in multiple organs ensue. The present studies quantitated rates of synthesis, absorption, and disposition of cholesterol, and whole body cholesterol pool size in a mouse model of CESD. In 50-day-old lal(-/-) and matching lal(+/+) mice fed a low-cholesterol diet, whole animal cholesterol content equalled 210 and 50 mg, respectively, indicating that since birth the lal(-/-) mice sequestered cholesterol at an average rate of 3.2 mg·day(-1)·animal(-1). The proportion of the body sterol pool contained in the liver of the lal(-/-) mice was 64 vs. 6.3% in their lal(+/+) controls. EC concentrations in the liver, spleen, small intestine, and lungs of the lal(-/-) mice were elevated 100-, 35-, 15-, and 6-fold, respectively. In the lal(-/-) mice, whole liver cholesterol synthesis increased 10.2-fold, resulting in a 3.2-fold greater rate of whole animal sterol synthesis compared with their lal(+/+) controls. The rate of cholesterol synthesis in the lal(-/-) mice exceeded that in the lal(+/+) controls by 3.7 mg·day(-1)·animal(-1). Fractional cholesterol absorption and fecal bile acid excretion were unchanged in the lal(-/-) mice, but their rate of neutral sterol excretion was 59% higher than in their lal(+/+) controls. Thus, in this model, the continual expansion of the body sterol pool is driven by the synthesis of excess cholesterol, primarily in the liver. Despite the severity of their disease, the median life span of the lal(-/-) mice was 355 days.


Assuntos
Doença do Armazenamento de Colesterol Éster/metabolismo , Ésteres do Colesterol/metabolismo , Fígado/metabolismo , Esterol Esterase/metabolismo , Animais , Doença do Armazenamento de Colesterol Éster/genética , Feminino , Absorção Intestinal , Mucosa Intestinal/metabolismo , Pulmão/metabolismo , Masculino , Camundongos , Baço/metabolismo , Esterol Esterase/deficiência , Esterol Esterase/genética
17.
Biomed Res Int ; 2014: 459823, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25025052

RESUMO

Alpha-1-antitrypsin deficiency (ATD) is one of the most common genetic causes of liver disease and is a prototype of liver diseases caused by the pathologic accumulation of aggregated mutant alpha-1-antitrypsin Z (ATZ) within liver cells. In the case of ATD-associated liver disease, the resulting "gain-of-function" toxicity can lead to serious clinical manifestations, including cirrhosis and hepatocellular carcinoma. Currently, the only definitive therapy for ATD-associated liver disease is liver transplantation, but recent efforts have demonstrated the exciting potential for novel therapies that target disposal of the mutant protein aggregates by harnessing a cellular homeostasis mechanism called autophagy. In this review, we will summarize research advances on autophagy and genetic liver diseases. We will discuss autophagy enhancer strategies for liver disease due to ATD and another genetic liver disease, inherited hypofibrinogenemia, caused by the proteotoxic effects of a misfolded protein. On the basis of recent evidence that autophagy plays a role in cellular lipid degradation, we also speculate about autophagy enhancer strategies for treatment of hepatic lipid storage diseases such as cholesterol ester storage disease.


Assuntos
Autofagia/genética , Terapia Genética , Deficiência de alfa 1-Antitripsina/genética , alfa 1-Antitripsina/genética , Doença do Armazenamento de Colesterol Éster/genética , Doença do Armazenamento de Colesterol Éster/terapia , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/patologia , Deficiência de alfa 1-Antitripsina/patologia , Deficiência de alfa 1-Antitripsina/terapia
18.
Z Gastroenterol ; 51(10): 1184-7, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24122380

RESUMO

Cholesteryl ester storage disease (CESD) is a rare, autosomal recessively inherited disorder resulting from deficient activity of lysosomal acid lipase (LAL). LAL is the key enzyme hydrolyzing cholesteryl esters and triglycerides stored in lysosomes after LDL receptor-mediated endocytosis. Mutations within the LIPA gene locus on chromosome 10q23.2-q23.3 may result either in the always fatal Wolman disease, where no LAL activity is found, or in the more benign disorder CESD with a reduced enzymatic activity, leading to massive accumulation of cholesteryl esters and triglycerides in many body tissues. CESD affects mostly the liver, the spectrum is ranging from isolated hepatomegaly to liver cirrhosis. Chronic diarrhea has been reported in some pediatric cases, while calcifications of the adrenal glands, the hallmark of Wolman disease, are rarely observed. Hypercholesterolemia and premature atherosclerosis are other typical disease manifestations. Hepatomegaly as a key finding has been reported in all 71 pediatric patients and in 134 of 135 adult cases in the literature. We present a 13-year-old boy with mildly elevated liver enzymes in the absence of hepatomegaly, finally diagnosed with CESD. Under pravastatine treatment, the patient has normal laboratory findings and is clinically unremarkable since 5 years of follow-up. To our knowledge, this is the first pediatric case of genetically and biopsy confirmed CESD without hepatomegaly, suggesting that this diagnosis can be easily missed. It further raises the question about the natural course and the therapy required for this oligosymptomatic form.


Assuntos
Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/genética , Erros de Diagnóstico/prevenção & controle , Predisposição Genética para Doença/genética , Esterol Esterase/genética , Adolescente , Diagnóstico Diferencial , Reações Falso-Negativas , Humanos , Masculino , Avaliação de Sintomas/métodos
19.
Arterioscler Thromb Vasc Biol ; 33(12): 2909-14, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24072694

RESUMO

OBJECTIVE: Autosomal recessive hypercholesterolemia is a rare inherited disorder, characterized by extremely high total and low-density lipoprotein cholesterol levels, that has been previously linked to mutations in LDLRAP1. We identified a family with autosomal recessive hypercholesterolemia not explained by mutations in LDLRAP1 or other genes known to cause monogenic hypercholesterolemia. The aim of this study was to identify the molecular pathogenesis of autosomal recessive hypercholesterolemia in this family. APPROACH AND RESULTS: We used exome sequencing to assess all protein-coding regions of the genome in 3 family members and identified a homozygous exon 8 splice junction mutation (c.894G>A, also known as E8SJM) in LIPA that segregated with the diagnosis of hypercholesterolemia. Because homozygosity for mutations in LIPA is known to cause cholesterol ester storage disease, we performed directed follow-up phenotyping by noninvasively measuring hepatic cholesterol content. We observed abnormal hepatic accumulation of cholesterol in the homozygote individuals, supporting the diagnosis of cholesterol ester storage disease. Given previous suggestions of cardiovascular disease risk in heterozygous LIPA mutation carriers, we genotyped E8SJM in >27 000 individuals and found no association with plasma lipid levels or risk of myocardial infarction, confirming a true recessive mode of inheritance. CONCLUSIONS: By integrating observations from Mendelian and population genetics along with directed clinical phenotyping, we diagnosed clinically unapparent cholesterol ester storage disease in the affected individuals from this kindred and addressed an outstanding question about risk of cardiovascular disease in LIPA E8SJM heterozygous carriers.


Assuntos
Doença do Armazenamento de Colesterol Éster/genética , Análise Mutacional de DNA , Exoma , Testes Genéticos/métodos , Hipercolesterolemia/genética , Mutação , Esterol Esterase/genética , Adulto , Biomarcadores/sangue , Colesterol/sangue , Doença do Armazenamento de Colesterol Éster/sangue , Doença do Armazenamento de Colesterol Éster/diagnóstico , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Feminino , Predisposição Genética para Doença , Hereditariedade , Homozigoto , Humanos , Hipercolesterolemia/sangue , Hipercolesterolemia/diagnóstico , Modelos Lineares , Fígado/metabolismo , Masculino , Pessoa de Meia-Idade , Linhagem , Fenótipo , Valor Preditivo dos Testes , Análise de Componente Principal , Triglicerídeos/sangue , Adulto Jovem , Hiperlipoproteinemia Tipo III
20.
J Clin Pathol ; 66(11): 918-23, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23999269

RESUMO

Cholesteryl ester storage disease (CESD) is an autosomal recessive lysosomal storage disorder caused by a variety of mutations of the LIPA gene. These cause reduced activity of lysosomal acid lipase, which results in accumulation of cholesteryl esters in lysosomes. If enzyme activity is very low/absent, presentation is in infancy with failure to thrive, malabsorption, hepatosplenomegaly and rapid early death (Wolman disease). With higher but still low enzyme activity, presentation is later in life with hepatic fibrosis, dyslipidaemia and early atherosclerosis.Identification of this rare disorder is difficult as it is essential to assay leucocyte acid phosphatase activity. An assay using specific inhibitors has now been developed that facilitates measurement in dried blood spots. Treatment of CESD has until now been limited to management of the dyslipidaemia, but this does not influence the liver effects. A new enzyme replacement therapy (Sebelipase) has now been developed that could change treatment options for the future.


Assuntos
Doença do Armazenamento de Colesterol Éster , Ésteres do Colesterol/metabolismo , Cirrose Hepática , Doenças Vasculares , Animais , Aterosclerose/diagnóstico , Aterosclerose/epidemiologia , Aterosclerose/genética , Aterosclerose/terapia , Doença do Armazenamento de Colesterol Éster/diagnóstico , Doença do Armazenamento de Colesterol Éster/epidemiologia , Doença do Armazenamento de Colesterol Éster/genética , Doença do Armazenamento de Colesterol Éster/terapia , Teste em Amostras de Sangue Seco , Dislipidemias/diagnóstico , Dislipidemias/epidemiologia , Dislipidemias/genética , Dislipidemias/terapia , Inibidores Enzimáticos/farmacologia , Humanos , Lactente , Cirrose Hepática/diagnóstico , Cirrose Hepática/epidemiologia , Cirrose Hepática/genética , Cirrose Hepática/terapia , Lisossomos/enzimologia , Redes e Vias Metabólicas , Mutação , Doenças Raras , Esterol Esterase/antagonistas & inibidores , Esterol Esterase/genética , Esterol Esterase/metabolismo , Doenças Vasculares/diagnóstico , Doenças Vasculares/epidemiologia , Doenças Vasculares/genética , Doenças Vasculares/terapia , Doença de Wolman/diagnóstico , Doença de Wolman/epidemiologia , Doença de Wolman/genética , Doença de Wolman/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA